Misinterpreted Myoepithelial Carcinoma of Salivary Gland: A Challenging and Potentially Significant Pitfall.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 23 2 2019
medline: 18 2 2020
entrez: 22 2 2019
Statut: ppublish

Résumé

Myoepithelial carcinoma (MECA) is an underrecognized challenging entity with a broad morphologic spectrum. Misinterpreting MECA is not uncommon as distinguishing it from its mimics, especially cellular myoepithelial-rich pleomorphic adenoma (PA), can be difficult. We described 21 histologically challenging cases of MECAs (16 MECA ex-PA and 5 MECA de novo). All MECAs ex-PA were intracapsular or minimally invasive except for 3 cases. Eighteen (86%) were initially misinterpreted as benign neoplasms, including PA (10), atypical PA (5), and myoepithelioma (3). The remaining 3 were initially diagnosed as malignant (MECA ex-PA) but were histologically challenging. Histologic features that were found most helpful in recognizing the malignant nature of MECA included: uniformly cellular myoepithelial proliferation with an expansile nodular lobulated pattern (all cases) and alternate hypocellular and hypercellular zonal distribution (76% of cases). Among the 16 MECA patients with follow-up, 14 (87.5%) progressed: 10 developed local recurrence and 5 distant metastases. In contrast, only one of 33 patients with cellular PA (control group) recurred locally. Ten of the 14 MECAs that progressed were MECA ex-PA, and 12 (85%) had an initial benign diagnosis. Two patients with MECA ex-PA died of their disease; one had an initial diagnosis of PA. MECA is a histologically challenging entity that closely mimics PA and seems to carry a significant risk of recurrence. Areas of clonal appearing cellular myoepithelial growth with an expansile nodular lobulated pattern and zonal cellular distribution distinguish the majority of MECAs and may serve as useful diagnostic histologic features to differentiate MECA from its benign mimics.

Identifiants

pubmed: 30789358
doi: 10.1097/PAS.0000000000001218
pmc: PMC7480003
mid: NIHMS1625174
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

601-609

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Références

Mod Pathol. 1996 Jun;9(6):652-7
pubmed: 8782203
J Oral Maxillofac Surg. 2015 Oct;73(10):1938-45
pubmed: 25896567
Hum Pathol. 2010 Jul;41(7):927-34
pubmed: 20338616
Kulak Burun Bogaz Ihtis Derg. 2010 May-Jun;20(3):129-36
pubmed: 20465538
Arch Otolaryngol Head Neck Surg. 2010 Jul;136(7):702-12
pubmed: 20644067
Arch Pathol Lab Med. 2009 Nov;133(11):1763-74
pubmed: 19886710
Histopathology. 2012 May;60(6B):E131-42
pubmed: 22486195
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Diagn Cytopathol. 1989;5(4):349-54
pubmed: 2558861
Int J Oral Maxillofac Surg. 2006 Jul;35(7):608-12
pubmed: 16540285
Am J Ophthalmol. 2013 Dec;156(6):1147-1158.e1
pubmed: 23972314
Am J Surg Pathol. 2015 Mar;39(3):338-48
pubmed: 25581728
Histopathology. 1998 Nov;33(5):485
pubmed: 9839176
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jul;110(1):85-93
pubmed: 20488733
Oncogene. 1998 Mar;16(11):1409-16
pubmed: 9525740
Head Neck Pathol. 2012 Sep;6(3):328-35
pubmed: 22485045
J Oral Med. 1976 Jul-Sep;31(3):69-71
pubmed: 184265
JAMA Oncol. 2017 Feb 1;3(2):244-255
pubmed: 27442865
Cancer. 1998 Oct 1;83(7):1292-9
pubmed: 9762928
Am J Surg Pathol. 2000 Jun;24(6):761-74
pubmed: 10843278
Histopathology. 1996 Apr;28(4):309-15
pubmed: 8732339
Histopathology. 2018 Jan;72(2):285-293
pubmed: 28796899
Am J Surg Pathol. 2015 Jul;39(7):931-8
pubmed: 25970687
Nat Commun. 2017 Oct 30;8(1):1197
pubmed: 29084941

Auteurs

Bin Xu (B)

Departments of Pathology.

Wadad Mneimneh (W)

Department of Pathology, University of South Alabama, Mobile, AL.

Dianne E Torrence (DE)

Department of Pathology, University of Florida, Gainesville, FL.

Kevin Higgins (K)

Surgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

David Klimstra (D)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Ronald Ghossein (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Nora Katabi (N)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH